Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.
Abstract: The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.
Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
March 26, 2024
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Tamar Auerbach-Nevo, Ashley Deanglis, Israel Nur
Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
March 5, 2024
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Israel Nur, Elena Grimberg, Itai Podoler, Inbar Gahali-Sass, Erez Ilan, Ronen Eavri
Abstract: The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.
Abstract: Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.
Type:
Grant
Filed:
December 13, 2017
Date of Patent:
January 2, 2024
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Tamar Auerbach-Nevo, Tali Negreanu-Gilboa, Hadas Alperin, Israel Nur
Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.
Type:
Grant
Filed:
February 4, 2021
Date of Patent:
August 1, 2023
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
Abstract: Provided is an applicator for the dispensing of a powder such as a pharmaceutical powder, on a target location. Also, provided are methods of applying a powder on a surface using the applicator.
Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
July 4, 2023
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
May 23, 2023
Assignees:
OMRIX BIOPHARMACEUTICALS LTD., ETHICON, INC.
Inventors:
Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
Abstract: Provided are methods and devices for dissolving solid protein compositions, such as solid compositions comprising fibrinogen, in an aqueous solvent. The methods comprise use of a closed container containing a volume of solid fibrinogen composition and a head space wherein the pressure within the headspace is sub-atmospheric. Aqueous solvent is introduced into the container while maintain the sub-atmospheric pressure, and subsequent to addition of the solvent, the size of the headspace is decreased to bring the pressure to atmospheric pressure. The devices are suitable for use in the disclosed method.
Type:
Grant
Filed:
March 10, 2020
Date of Patent:
April 25, 2023
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Erez Ilan, Kfir Regev, Dana Leitman, Israel Nur, Moti Meron, John Goodman
Abstract: Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
February 21, 2023
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Inbar Gahali-Sass, Israel Nur, Erez Ilan, Ronen Eavri
Abstract: The present invention is directed to a dry pad comprising pectin, a divalent cation and thrombin and to its preparation. Preferably, the density of pectin in the dry pad of the invention ranges from about equal to or higher than 1% to lower than 7% (w/v). The pad according to the invention comprises pectin having a low methoxyl content.
Abstract: The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.
Abstract: The present invention is directed to compounds, methods for stabilizing thrombin activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition can be reversed with an antisense oligonucleotide.
Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
January 18, 2022
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Roberto Meidler, Oleg Belyaev, Liliana Bar, Israel Nur
Abstract: Provided is a method for purifying ?-thrombin and for quantifying ?-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified ?-thrombin. The method can also be used for purification and/or quantification of ?-thrombin.
Type:
Grant
Filed:
December 12, 2019
Date of Patent:
October 19, 2021
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Tamar Auerbach-Nevo, Nadav Orr, Israel Nur
Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
September 21, 2021
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Tamar Auerbach-Nevo, Ashley Deanglis, Israel Nur
Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
June 29, 2021
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach